Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel H Palmer

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|September 14, 2012
Impact of restricting access to high-cost medications for hepatocellular carcinomaYuk Ting Ma, Daniel H Palmer
Cancer Metastasis Reviews|August 8, 2015
Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinomaDaniel H Palmer, Phillip J Johnson
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2009
CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signalsTaha Elmetwali, Lawrence S Young, Daniel H Palmer
Current Opinion in Molecular Therapeutics|November 19, 2002
Clinical experience with adenovirus in cancer therapyDaniel H Palmer, Vivien Mautner, David J Kerr
Trends in Biotechnology|December 29, 2005
Cancer gene-therapy: clinical trialsDaniel H Palmer, Lawrence S Young, Vivien Mautner
Journal of Hepatology|January 20, 2020
Role of locoregional therapies in the wake of systemic therapyDaniel H Palmer, Katerina Malagari, Laura M Kulik
Journal of Biomedicine & Biotechnology|April 11, 2003
Taking Gene Therapy into the ClinicDaniel H. Palmer, Ming-Jen Chen, David J. Kerr
British Medical Bulletin|November 8, 2002
Gene therapy for colorectal cancerDaniel H Palmer, Ming-Jen Chen, David J Kerr
Expert Opinion on Investigational Drugs|November 30, 2004
Systemic therapies for hepatocellular carcinomaDaniel H Palmer, Syed A Hussain, Philip J Johnson
Expert Opinion on Biological Therapy|June 7, 2005
Gene- and immunotherapy for hepatocellular carcinomaDaniel H Palmer, Syed A Hussain, Philip J Johnson
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Expert Review of Pharmacoeconomics & Outcomes Research|September 14, 2012
Impact of restricting access to high-cost medications for hepatocellular carcinomaYuk Ting Ma, Daniel H Palmer
Cancer Metastasis Reviews|August 8, 2015
Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinomaDaniel H Palmer, Phillip J Johnson
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2009
CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signalsTaha Elmetwali, Lawrence S Young, Daniel H Palmer
Current Opinion in Molecular Therapeutics|November 19, 2002
Clinical experience with adenovirus in cancer therapyDaniel H Palmer, Vivien Mautner, David J Kerr
Trends in Biotechnology|December 29, 2005
Cancer gene-therapy: clinical trialsDaniel H Palmer, Lawrence S Young, Vivien Mautner
Journal of Hepatology|January 20, 2020
Role of locoregional therapies in the wake of systemic therapyDaniel H Palmer, Katerina Malagari, Laura M Kulik
Journal of Biomedicine & Biotechnology|April 11, 2003
Taking Gene Therapy into the ClinicDaniel H. Palmer, Ming-Jen Chen, David J. Kerr
British Medical Bulletin|November 8, 2002
Gene therapy for colorectal cancerDaniel H Palmer, Ming-Jen Chen, David J Kerr
Expert Opinion on Investigational Drugs|November 30, 2004
Systemic therapies for hepatocellular carcinomaDaniel H Palmer, Syed A Hussain, Philip J Johnson
Expert Opinion on Biological Therapy|June 7, 2005
Gene- and immunotherapy for hepatocellular carcinomaDaniel H Palmer, Syed A Hussain, Philip J Johnson
Pageof 8